Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 76-41-5
Drug Levels and Effects
Summary of Use during Lactation
No data are available on the use of oxymorphone during breastfeeding. Maternal use of oral opioids during breastfeeding can cause infant drowsiness, which may progress to rare but severe central nervous system depression. Newborn infants seem to be particularly sensitive to the effects of even small dosages of narcotic analgesics.[1] If oxymorphone is required by the mother of a newborn, it is not a reason to discontinue breastfeeding; however, once the mother's milk comes in, it is best to provide pain control with a nonnarcotic analgesic and limit maternal intake of oral oxymorphone for 2 to 3 days at low dosages, with close infant monitoring. If the baby shows signs of increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness, a physician should be contacted immediately. Other agents are preferred over oxymorphone during breastfeeding.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Narcotics can increase serum prolactin.[2] However, the prolactin level in a mother with established lactation may not affect her ability to breastfeed.
Alternate Drugs to Consider
References
- 1.
- Ito S. Opioids in breast milk: Pharmacokinetic principles and clinical implications. J Clin Pharmacol 2018;58 (Suppl 10):S151-S163. [PubMed: 30248201]
- 2.
- Tolis G, Dent R, Guyda H. Opiates, prolactin, and the dopamine receptor. J Clin Endocrinol Metab 1978;47:200-3. [PubMed: 263291]
Substance Identification
Substance Name
Oxymorphone
CAS Registry Number
76-41-5
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- Review Hydromorphone.[Drugs and Lactation Database (...]Review Hydromorphone.. Drugs and Lactation Database (LactMed®). 2006
- Review Hydrocodone.[Drugs and Lactation Database (...]Review Hydrocodone.. Drugs and Lactation Database (LactMed®). 2006
- Review Piritramide.[Drugs and Lactation Database (...]Review Piritramide.. Drugs and Lactation Database (LactMed®). 2006
- Review Fentanyl.[Drugs and Lactation Database (...]Review Fentanyl.. Drugs and Lactation Database (LactMed®). 2006
- Review Pentazocine.[Drugs and Lactation Database (...]Review Pentazocine.. Drugs and Lactation Database (LactMed®). 2006
- Oxymorphone - Drugs and Lactation Database (LactMed®)Oxymorphone - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...